{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:46:04Z","timestamp":1790700364849,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2015,5,10]],"date-time":"2015-05-10T00:00:00Z","timestamp":1431216000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1007\/s40618-015-0301-z","type":"journal-article","created":{"date-parts":[[2015,5,9]],"date-time":"2015-05-09T01:19:02Z","timestamp":1431134342000},"page":"1159-1166","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":65,"title":["Ipilimumab-induced hypophysitis: review of the literature"],"prefix":"10.1007","volume":"38","author":[{"given":"P. B.","family":"Araujo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. C. A.","family":"Coelho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Arruda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. R.","family":"Gadelha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. V.","family":"Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,5,10]]},"reference":[{"issue":"25","key":"301_CR1","doi-asserted-by":"crossref","first-page":"6043","DOI":"10.1200\/JCO.2005.06.205","volume":"23","author":"P Attia","year":"2005","unstructured":"Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Restifo NP, Haworth LR, Levy C, Mavroukakis SA, Nichol G, Yellin MJ, Rosenberg SA (2005) Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol Off J Am Soc Clin Oncol 23(25):6043\u20136053. doi: 10.1200\/JCO.2005.06.205","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"14","key":"301_CR2","doi-asserted-by":"crossref","first-page":"8372","DOI":"10.1073\/pnas.1533209100","volume":"100","author":"GQ Phan","year":"2003","unstructured":"Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Restifo NP, Haworth LR, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA, Duray PH, Steinberg SM, Allison JP, Davis TA, Rosenberg SA (2003) Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 100(14):8372\u20138377. doi: 10.1073\/pnas.1533209100","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"301_CR3","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbe C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ (2010) Improved survival with ipilimumab in patients with metastatic melanoma. New Engl J Med 363(8):711\u2013723. doi: 10.1056\/NEJMoa1003466","journal-title":"New Engl J Med"},{"key":"301_CR4","doi-asserted-by":"crossref","unstructured":"Faje AT, Sullivan R, Lawrence D, Tritos NA, Fadden R, Klibanski A, Nachtigall L (2014) Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J Clin Endocrinol Metab doi: 10.1210\/jc.2014-2306","DOI":"10.1210\/jc.2014-2306"},{"issue":"4","key":"301_CR5","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1634\/theoncologist.2011-0404","volume":"17","author":"F Torino","year":"2012","unstructured":"Torino F, Barnabei A, De Vecchis L, Salvatori R, Corsello SM (2012) Hypophysitis induced by monoclonal antibodies to cytotoxic T lymphocyte antigen 4: challenges from a new cause of a rare disease. Oncologist 17(4):525\u2013535. doi: 10.1634\/theoncologist.2011-0404","journal-title":"Oncologist"},{"issue":"6","key":"301_CR6","doi-asserted-by":"crossref","first-page":"R153","DOI":"10.1530\/EJE-13-0434","volume":"169","author":"F Torino","year":"2013","unstructured":"Torino F, Barnabei A, Paragliola RM, Marchetti P, Salvatori R, Corsello SM (2013) Endocrine side-effects of anti-cancer drugs: mAbs and pituitary dysfunction: clinical evidence and pathogenic hypotheses. Eur J Endocrinol Eur Federation Endocr Soc 169(6):R153\u2013R164. doi: 10.1530\/eje-13-0434","journal-title":"Eur J Endocrinol Eur Federation Endocr Soc"},{"issue":"4","key":"301_CR7","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1210\/jc.2012-4075","volume":"98","author":"SM Corsello","year":"2013","unstructured":"Corsello SM, Barnabei A, Marchetti P, De Vecchis L, Salvatori R, Torino F (2013) Endocrine side effects induced by immune checkpoint inhibitors. J Clin Endocrinol metabolism 98(4):1361\u20131375. doi: 10.1210\/jc.2012-4075","journal-title":"J Clin Endocrinol metabolism"},{"issue":"1","key":"301_CR8","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11102-009-0193-z","volume":"13","author":"T Dillard","year":"2010","unstructured":"Dillard T, Yedinak CG, Alumkal J, Fleseriu M (2010) Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes. Pituitary 13(1):29\u201338. doi: 10.1007\/s11102-009-0193-z","journal-title":"Pituitary"},{"issue":"5","key":"301_CR9","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1053\/j.seminoncol.2010.09.007","volume":"37","author":"AM Giacomo Di","year":"2010","unstructured":"Di Giacomo AM, Biagioli M, Maio M (2010) The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications. Semin Oncol 37(5):499\u2013507. doi: 10.1053\/j.seminoncol.2010.09.007","journal-title":"Semin Oncol"},{"key":"301_CR10","first-page":"489","volume":"5","author":"SP Patel","year":"2011","unstructured":"Patel SP, Woodman SE (2011) Profile of ipilimumab and its role in the treatment of metastatic melanoma. Drug design, development and therapy 5:489\u2013495. doi: 10.2147\/DDDT.S10945","journal-title":"Drug design, development and therapy"},{"key":"301_CR11","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2147\/OTT.S57335","volume":"7","author":"G Della Vittoria Scarpati","year":"2014","unstructured":"Della Vittoria Scarpati G, Fusciello C, Perri F, Sabbatino F, Ferrone S, Carlomagno C, Pepe S (2014) Ipilimumab in the treatment of metastatic melanoma: management of adverse events. OncoTargets and therapy 7:203\u2013209. doi: 10.2147\/ott.s57335","journal-title":"OncoTargets and therapy"},{"key":"301_CR12","doi-asserted-by":"crossref","first-page":"857519","DOI":"10.1155\/2013\/857519","volume":"2013","author":"A Tarhini","year":"2013","unstructured":"Tarhini A (2013) Immune-mediated adverse events associated with ipilimumab ctla-4 blockade therapy: the underlying mechanisms and clinical management. Scientifica 2013:857519. doi: 10.1155\/2013\/857519","journal-title":"Scientifica"},{"issue":"5","key":"301_CR13","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1053\/j.seminoncol.2010.09.003","volume":"37","author":"KC Kaehler","year":"2010","unstructured":"Kaehler KC, Piel S, Livingstone E, Schilling B, Hauschild A, Schadendorf D (2010) Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management. Semin Oncol 37(5):485\u2013498. doi: 10.1053\/j.seminoncol.2010.09.003","journal-title":"Semin Oncol"},{"issue":"5","key":"301_CR14","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1053\/j.seminoncol.2010.09.004","volume":"37","author":"P Boasberg","year":"2010","unstructured":"Boasberg P, Hamid O, O\u2019Day S (2010) Ipilimumab: unleashing the power of the immune system through CTLA-4 blockade. Semin Oncol 37(5):440\u2013449. doi: 10.1053\/j.seminoncol.2010.09.004","journal-title":"Semin Oncol"},{"key":"301_CR15","doi-asserted-by":"crossref","unstructured":"Yang JC, Hughes M, Kammula U, Royal R, Sherry RM, Topalian SL, Suri KB, Levy C, Allen T, Mavroukakis S, Lowy I, White DE, Rosenberg SA (2007) Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother 30(8):825\u2013830. doi: 10.1097\/CJI.0b013e318156e47e","DOI":"10.1097\/CJI.0b013e318156e47e"},{"key":"301_CR16","doi-asserted-by":"crossref","unstructured":"Maker AV, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Hughes M, Yellin MJ, Haworth LR, Levy C, Allen T, Mavroukakis SA, Attia P, Rosenberg SA (2006) Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J Immunother 29(4):455-463. doi: 10.1097\/01.cji.0000208259.73167.58","DOI":"10.1097\/01.cji.0000208259.73167.58"},{"key":"301_CR17","doi-asserted-by":"crossref","unstructured":"Blansfield JA, Beck KE, Tran K, Yang JC, Hughes MS, Kammula US, Royal RE, Topalian SL, Haworth LR, Levy C, Rosenberg SA, Sherry RM (2005) Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother 28(6):593\u2013598","DOI":"10.1097\/01.cji.0000178913.41256.06"},{"key":"301_CR18","author":"J Marlier","year":"2014","unstructured":"Marlier J, Cocquyt V, Brochez L, Van Belle S, Kruse V (2014) Ipilimumab, not just another anti-cancer therapy: hypophysitis as side effect illustrated by four case-reports. Endocrine. doi: 10.1007\/s12020-014-0199-9","journal-title":"Endocrine"},{"key":"301_CR19","doi-asserted-by":"crossref","unstructured":"Iwama S, De Remigis A, Callahan MK, Slovin SF, Wolchok JD, Caturegli P (2014) Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Science translational medicine 6(230):230ra245. doi: 10.1126\/scitranslmed.3008002","DOI":"10.1126\/scitranslmed.3008002"},{"issue":"5","key":"301_CR20","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1210\/er.2004-0011","volume":"26","author":"P Caturegli","year":"2005","unstructured":"Caturegli P, Newschaffer C, Olivi A, Pomper MG, Burger PC, Rose NR (2005) Autoimmune hypophysitis. Endocr Rev 26(5):599\u2013614. doi: 10.1210\/er.2004-0011","journal-title":"Endocr Rev"},{"issue":"3","key":"301_CR21","first-page":"351","volume":"18","author":"L Min","year":"2012","unstructured":"Min L, Vaidya A, Becker C (2012) Association of ipilimumab therapy for advanced melanoma with secondary adrenal insufficiency: a case series. Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol 18(3):351\u2013355. doi: 10.4158\/ep11273.or","journal-title":"Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol"},{"issue":"21","key":"301_CR22","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","volume":"30","author":"JS Weber","year":"2012","unstructured":"Weber JS, Kahler KC, Hauschild A (2012) Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol Off J Am Soc Clin Oncol 30(21):2691\u20132697. doi: 10.1200\/jco.2012.41.6750","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"301_CR23","doi-asserted-by":"crossref","unstructured":"Bronstein Y, Ng CS, Hwu P, Hwu WJ (2011) Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy. AJR Am J Roentgenol 197 (6):w992\u2013w1000. doi: 10.2214\/ajr.10.6198","DOI":"10.2214\/AJR.10.6198"},{"issue":"4","key":"301_CR24","first-page":"E8","volume":"16","author":"DR Fassett","year":"2004","unstructured":"Fassett DR, Couldwell WT (2004) Metastases to the pituitary gland. Neurosurg Focus 16(4):E8","journal-title":"Neurosurg Focus"},{"issue":"1","key":"301_CR25","first-page":"154","volume":"18","author":"YY Wang","year":"2011","unstructured":"Wang YY, Norris A, du Plessis D, Gnanalingham KK (2011) Melanoma of the sellar region. J Clin Neurosci Off J Neurosurg Soc Australas 18(1):154\u2013156. doi: 10.1016\/j.jocn.2010.07.111","journal-title":"J Clin Neurosci Off J Neurosurg Soc Australas"},{"key":"301_CR26","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.clineuro.2014.06.011","volume":"125","author":"Y Chodakiewitz","year":"2014","unstructured":"Chodakiewitz Y, Brown S, Boxerman JL, Brody JM, Rogg JM (2014) Ipilimumab treatment associated pituitary hypophysitis: clinical presentation and imaging diagnosis. Clin Neurol Neurosurg 125:125\u2013130. doi: 10.1016\/j.clineuro.2014.06.011","journal-title":"Clin Neurol Neurosurg"},{"issue":"1","key":"301_CR27","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s12020-012-9654-7","volume":"42","author":"A Glezer","year":"2012","unstructured":"Glezer A, Bronstein MD (2012) Pituitary autoimmune disease: nuances in clinical presentation. Endocrine 42(1):74\u201379. doi: 10.1007\/s12020-012-9654-7","journal-title":"Endocrine"},{"issue":"5","key":"301_CR28","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.beem.2009.05.009","volume":"23","author":"R Carpinteri","year":"2009","unstructured":"Carpinteri R, Patelli I, Casanueva FF, Giustina A (2009) Pituitary tumours: inflammatory and granulomatous expansive lesions of the pituitary. Best Pract Res Clin Endocrinol Metab 23(5):639\u2013650. doi: 10.1016\/j.beem.2009.05.009","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"22 Pt 1","key":"301_CR29","doi-asserted-by":"crossref","first-page":"6681","DOI":"10.1158\/1078-0432.CCR-07-0187","volume":"13","author":"SG Downey","year":"2007","unstructured":"Downey SG, Klapper JA, Smith FO, Yang JC, Sherry RM, Royal RE, Kammula US, Hughes MS, Allen TE, Levy CL, Yellin M, Nichol G, White DE, Steinberg SM, Rosenberg SA (2007) Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res Off J Am Assoc Cancer Res 13(22 Pt 1):6681\u20136688. doi: 10.1158\/1078-0432.CCR-07-0187","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"2","key":"301_CR30","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s10014-008-0234-8","volume":"25","author":"T Abe","year":"2008","unstructured":"Abe T (2008) Lymphocytic infundibulo-neurohypophysitis and infundibulo-panhypophysitis regarded as lymphocytic hypophysitis variant. Brain Tumor Pathol 25(2):59\u201366. doi: 10.1007\/s10014-008-0234-8","journal-title":"Brain Tumor Pathol"},{"issue":"4","key":"301_CR31","first-page":"327","volume":"150","author":"N Beressi","year":"1999","unstructured":"Beressi N, Beressi JP, Cohen R, Modigliani E (1999) Lymphocytic hypophysitis. A review of 145 cases. Ann Med Interne 150(4):327\u2013341","journal-title":"Ann Med Interne"},{"issue":"36","key":"301_CR32","doi-asserted-by":"crossref","first-page":"5950","DOI":"10.1200\/JCO.2008.16.1927","volume":"26","author":"JS Weber","year":"2008","unstructured":"Weber JS, O\u2019Day S, Urba W, Powderly J, Nichol G, Yellin M, Snively J, Hersh E (2008) Phase I\/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol Off J Am Soc Clin Oncol 26(36):5950\u20135956. doi: 10.1200\/JCO.2008.16.1927","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"17","key":"301_CR33","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1158\/1078-0432.CCR-09-1024","volume":"15","author":"J Weber","year":"2009","unstructured":"Weber J, Thompson JA, Hamid O, Minor D, Amin A, Ron I, Ridolfi R, Assi H, Maraveyas A, Berman D, Siegel J, O\u2019Day SJ (2009) A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res Off J Am Assoc Cancer Res 15(17):5591\u20135598. doi: 10.1158\/1078-0432.CCR-09-1024","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-015-0301-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40618-015-0301-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-015-0301-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T19:03:41Z","timestamp":1559502221000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40618-015-0301-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,10]]},"references-count":33,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["301"],"URL":"https:\/\/doi.org\/10.1007\/s40618-015-0301-z","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,10]]}}}